Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III study of KN035 plus gemcitabine and oxaliplatin versus gemcitabine and oxaliplatin as first-line treatment for unresectable or metastatic biliary tract cancer
CTR20180332Phase 3Completed
- Sponsor
- Alphamab Oncology
- Start
- Apr 2018
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of envafolimab, gemcitabine, oxaliplatin in biliary cancer, gallbladder cancer, cholangiocarcinoma (CCA), sponsored by Alphamab Oncology. Started Apr 2018; status: completed.
02
Drugs
envafolimabgemcitabineoxaliplatin
03
Conditions
biliary cancergallbladder cancercholangiocarcinoma (CCA)
Beyond the preview
Go deeper on CTR20180332.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20180332.